Art. 62 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2022cited 20×
1.

Where, in accordance with this Regulation, any of the Committees referred to in Article 56(1) is required to evaluate a medicinal product for human use, it shall appoint one of its members to act as rapporteur, taking into account existing expertise in the Member State. The Committee concerned may appoint a second member to act as co-rapporteur.

A rapporteur appointed for this purpose by the Pharmacovigilance Risk Assessment Committee shall closely collaborate with the rapporteur appointed by the Committee for Medicinal Products for Human Use or the Reference Member State for the medicinal product for human use concerned.

When consulting the scientific advisory groups referred to in Article 56(2), the Committee shall forward to them the draft assessment report or reports drawn up by the rapporteur or the co-rapporteur. The opinion issued by the scientific advisory group shall be forwarded to the chairman of the relevant committee in such a way as to ensure that the deadlines laid down in Article 6(3) are met.

The substance of the opinion shall be included in the assessment report published pursuant to Article 13(3).

If there is a request for re-examination of one of its opinions where this possibility is provided for in Union law, the Committee concerned shall appoint a different rapporteur and, where necessary, a different co-rapporteur from those appointed for the initial opinion. The re-examination procedure may deal only with the points of the opinion initially identified by the applicant and may be based only on the scientific data available when the Committee adopted the initial opinion. The applicant may request that the Committee consult a scientific advisory group in connection with the re-examination.

2.

Member States shall transmit to the Agency the names of national experts with proven experience in the evaluation of medicinal products for human use and veterinary medicinal products who, taking into account Article 63(2), would be available to serve on working parties or scientific advisory groups of any of the committees referred to in Article 56(1), together with an indication of their qualifications and specific areas of expertise.

The Agency shall establish and maintain a list of accredited experts. That list shall include the national experts referred to in the first subparagraph and any other experts appointed by the Agency or the Commission, and shall be updated.

3.

The provision of services by rapporteurs or experts shall be governed by a written contract between the Agency and the person concerned, or where appropriate between the Agency and his employer.

The person concerned, or his employer, shall be remunerated in accordance with a scale of fees to be included in the financial arrangements established by the Management Board.

The first and second subparagraphs shall also apply to the work of rapporteurs in the coordination group as regards the fulfilment of its tasks in accordance with Articles 107c, 107e, 107g, 107k and 107q of Directive 2001/83/EC.

4.

The performance of scientific services for which there are several potential providers may result in a call for an expression of interest, if the scientific and technical context allows, and if it is compatible with the tasks of the Agency, in particular to ensure a high level of public health protection.

The Management Board shall adopt the appropriate procedures on a proposal from the Executive Director.

5.

The Agency or any of the committees referred to in Article 56(1) may use the services of experts for the discharge of other specific tasks for which they are responsible.

The 10 that are cited most themselves, of 20.

  • Directive (EU) 2001/8332Law

    … становището си в съответствие с четвъртата алинея на член 62, параграф 1 от Регламент (ЕО) № 726/2004. Причините за постигнатото …

  • Judgment of the Court (Fourth Chamber) of 27 March 2019. Dr. August Wolff GmbH & Co. KG Arzneimittel and Remedia d.o.o. v European CommissioDecision

    In the third place, in accordance with the first paragraph of Article 62(1) of Regulation No 726/2004, where the Committee is required to evaluate a medicinal product for human use, it is to appoint one of its members to act as rapporteur …

    27 Mar 2019 · 62016CJ0680

  • Arrêt du Tribunal (cinquième chambre) du 11 décembre 2014. PP Nature-Balance Lizenz GmbH contre Commission européenne.Decision

    … Mitberichterstatter für die Beurteilung des Antrags auf Überprüfung des ersten Gutachtens des Ausschusses gemäß Art. 62 Abs. 1 Unterabs. 4 der Verordnung (EG) Nr. 726/2004 des Europäischen Parlaments und des Rates vom 31. März 2004 …

    11 Dec 2014 · 62013TJ0189

  • Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…Lawamends

  • Judgment of the General Court (Sixth Chamber) of 28 October 2020. Pharma Mar, SA v European Commission.Decision

    On 3 January 2018, the applicant submitted to the EMA a request for re-examination of the CHMP’s opinion and then, on 14 February 2018, submitted the detailed grounds for its request, pursuant to Article 9(2) of Regulation No 726/2004. …

    28 Oct 2020 · 62018TJ0594

  • Directive (EU) 2004/2732Law

    … vor. Innerhalb von 60 Tagen nach Erhalt der Begründung des Gesuchs überprüft der Ausschuss sein Gutachten gemäß Artikel 62 Absatz 1 Unterabsatz 4 der Verordnung (EG) Nr. 726/2004. Die Gründe für die erzielten Schlussfolgerungen …

  • Regulation (EU) 2019/6139Law

    … групи от списъците с акредитирани експерти, посочени в член 62, параграф 2, втора алинея от Регламент (ЕО) № 726/2004, и редът за …

  • Judgment of the General Court (Fourth Chamber) of 19 September 2019. GE Healthcare A/S v European Commission.Decision

    It should be noted, in that regard, that Professor T. was neither a member of the PRAC nor the CHMP, but only a member of an expert group set up by the PRAC under Article 32 of Directive 2001/83. The PRAC designated those experts from a …

    19 Sep 2019 · 62017TJ0783

  • Judgment of the Court (Third Chamber) of 22 June 2023. Federal Republic of Germany v European Commission.Decision

    On the basis of Article 9(2) of Regulation No 726/2004, Pharma Mar submitted to the EMA, on 3 January 2018, a request for re-examination of the CHMP’s opinion, accompanied by a request for consultation with a scientific advisory group, …

    22 Jun 2023 · 62021CJ0006

  • Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision

    En premier lieu, la requérante estime que le CHMP n’avait pas de pouvoir d’appréciation pour décider qu’un comité d’experts ad hoc était compétent, dès lors que la demande expresse de la requérante visait le GSC …

    2 Mar 2022 · 62020TJ0556